Cargando…
Prognostic and predictive biomarker developments in multiple myeloma
New approaches to stratify multiple myeloma patients based on prognosis and therapeutic decision-making, or prediction, are needed since patients are currently managed in a similar manner regardless of individual risk factors or disease characteristics. However, despite new and improved biomarkers f...
Autores principales: | Wallington-Beddoe, Craig T., Mynott, Rachel L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8461914/ https://www.ncbi.nlm.nih.gov/pubmed/34556161 http://dx.doi.org/10.1186/s13045-021-01162-7 |
Ejemplares similares
-
Novel therapies for multiple myeloma
por: Wallington-Beddoe, Craig T., et al.
Publicado: (2017) -
Enhancing ER stress in myeloma
por: Wallington-Beddoe, Craig T., et al.
Publicado: (2017) -
Ferroptosis in Haematological Malignancies and Associated Therapeutic Nanotechnologies
por: Mynott, Rachel L., et al.
Publicado: (2023) -
Desmoglein‐2 expression is an independent predictor of poor prognosis patients with multiple myeloma
por: Ebert, Lisa M., et al.
Publicado: (2021) -
Targeting sphingolipid metabolism as an approach for combination therapies in haematological malignancies
por: Lewis, Alexander C., et al.
Publicado: (2018)